Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.32 |
| ▸ | ITGAV | P06756 | 4/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884493 | 0.95 | WDR5 (0.34) | ALDH1A1JAK2JAK1TYK2P2RX1 | |
| SCHEMBL23875072 | 0.86 | NISCH (0.38) | ITGB3ITGAVITGA2BP2RX1PDCD1 | |
| SCHEMBL21884640 | 0.85 | NISCH (0.35) | JAK2JAK1TYK2ALOX5 | |
| SCHEMBL21884363 | 0.85 | NISCH (0.41) | GRM4 | |
| SCHEMBL21884636 | 0.84 | NISCH (0.34) | JAK2JAK1TYK2CD274ALOX5 | |
| SCHEMBL21884463 | 0.82 | NISCH (0.38) | PDCD1CD274 | |
| SCHEMBL24066340 | 0.82 | NISCH (0.35) | CD274 | |
| SCHEMBL21884353 | 0.82 | GPR6 (0.32) | ITGB3ITGB1ITGAVITGA2BITGB5 | |
| SCHEMBL21884366 | 0.81 | JAK2 (0.35) | JAK2CD274 | |
| SCHEMBL21884358 | 0.81 | EPAS1 (0.38) | ALDH1A1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | ITGB3 4264/4885ITGB1 4542/4885ITGAV 3704/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | ITGB3 3532/4885ITGB1 3676/4885ITGAV 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.